ArticleEndocrine connections2018
NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features.
Article in Endocrine connections, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- The effect ofFrontiers in endocrinology · 2025Pooled it
- Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.Endocrine · 2020Pooled it
- Clinical, Pathological, and Molecular Characteristics Correlating to the Occurrence of Radioiodine Refractory Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Predicting radioiodine therapy response in advanced and recurrent thyroid cancer.Endocrine-related cancer · 2026Article
- Spatial and single-nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers.Molecular oncology · 2026Article
- Article
- Assessing the sodium-iodide symporter (NIS) in pediatric differentiated thyroid carcinoma.European thyroid journal · 2026Article
- Targeted therapy in thyroid cancer: molecular alterations and clinical management.Frontiers in endocrinology · 2026Review
- Case Report: Synchronous primary lung and thyroid cancers - management informed by multimodal imaging and pathologic correlation.Frontiers in oncology · 2026Article
- Age-dependent effects of surgical approach in T3b differentiated thyroid carcinoma: a population-based analysis using machine learning.Endocrine-related cancer · 2025Article
- Gene Expression Analysis of Papillary Thyroid Carcinoma With Lymph Node Metastasis and Radioiodine Refractivity.Cureus · 2025Article
- CouldDiagnostics (Basel, Switzerland) · 2024Article
- Regulation of iodine-glucose flip-flop in SW1736 anaplastic thyroid cancer cell line.Journal of endocrinological investigation · 2024Article
- Computational Analysis Suggests That AsnGTT 3'-tRNA-Derived Fragments Are Potential Biomarkers in Papillary Thyroid Carcinoma.International journal of molecular sciences · 2024Article
- Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma.World journal of nuclear medicine · 2024Article
- Prediction of the Aggressive Clinical Course of Papillary Thyroid Carcinoma Based on Fine Needle Aspiration Biopsy Molecular Testing.International journal of molecular sciences · 2024Article
- Article
- Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers.European thyroid journal · 2024Article
- Article
- Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2.Molecular cancer research : MCR · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid cancer therapy is based on surgery followed by radioiodine treatment. The incorporation of radioiodine by cancer cells is mediated by sodium iodide symporter (NIS) (codified by the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.